Company · Mississauga, Ontario, Canada
Astrazeneca Canada Inc
Everything this company holds in Health Canada’s product databases, as the company’s name is spelled there.
- Drug products (DIN)
- 128
- 58 authorized now
- Natural health products
- 0
- 0 active licences
- Medical device licences
- 4
- 0 active
- Notices of Compliance
- 460
Drug products
Authorized products first.
| Name | DIN | Status | Status since |
|---|---|---|---|
| ARIMIDEX | 02224135 | Marketed | |
| BREZTRI AEROSPHERE | 02518058 | Marketed | |
| BRICANYL TURBUHALER | 00786616 | Marketed | |
| BRILINTA | 02368544 | Marketed | |
| BRILINTA | 02455005 | Marketed | |
| CALQUENCE | 02535696 | Marketed | |
| CRESTOR - 10MG | 02247162 | Marketed | |
| CRESTOR - 20MG | 02247163 | Marketed | |
| CRESTOR - 40MG | 02247164 | Marketed | |
| CRESTOR - 5MG | 02265540 | Marketed | |
| DAXAS | 02359456 | Marketed | |
| ENHERTU | 02514400 | Marketed | |
| FASENRA | 02473232 | Marketed | |
| FASENRA PEN | 02496135 | Marketed | |
| FASLODEX | 02248624 | Marketed | |
| FLUMIST | 02352621 | Marketed | |
| FORXIGA | 02435462 | Marketed | |
| FORXIGA | 02435470 | Marketed | |
| IMFINZI | 02468816 | Marketed | |
| IMJUDO | 02541009 | Marketed | |
| IRESSA | 02248676 | Marketed | |
| LOKELMA | 02490714 | Marketed | |
| LOKELMA | 02490722 | Marketed | |
| LYNPARZA | 02475200 | Marketed | |
| LYNPARZA | 02475219 | Marketed | |
| NEXIUM | 02300524 | Marketed | |
| NEXIUM - 20MG | 02244521 | Marketed | |
| NEXIUM - 40MG | 02244522 | Marketed | |
| ONGLYZA | 02333554 | Marketed | |
| ONGLYZA | 02375842 | Marketed | |
| OXEZE TURBUHALER | 02237224 | Marketed | |
| OXEZE TURBUHALER | 02237225 | Marketed | |
| PULMICORT NEBUAMP 0.125 MG/ML | 02229099 | Marketed | |
| PULMICORT NEBUAMP 0.25 MG/ML | 01978918 | Marketed | |
| PULMICORT NEBUAMP 0.5 MG/ML | 01978926 | Marketed | |
| PULMICORT TURBUHALER | 00851752 | Marketed | |
| PULMICORT TURBUHALER | 00852074 | Marketed | |
| PULMICORT TURBUHALER | 00851760 | Marketed | |
| SAPHNELO | 02522845 | Marketed | |
| SAPHNELO | 02566338 | Marketed | |
| SYMBICORT 100 TURBUHALER | 02245385 | Marketed | |
| SYMBICORT 200 TURBUHALER | 02245386 | Marketed | |
| TAGRISSO | 02456214 | Marketed | |
| TAGRISSO | 02456222 | Marketed | |
| TEZSPIRE | 02529548 | Marketed | |
| TEZSPIRE | 02529556 | Marketed | |
| TRUQAP | 02544733 | Marketed | |
| TRUQAP | 02544741 | Marketed | |
| WAINUA | 02548909 | Marketed | |
| XIGDUO | 02449935 | Marketed | |
| XIGDUO | 02449943 | Marketed | |
| CALQUENCE | 02491788 | Dormant | |
| ETCAMAH | 02570572 | Approved | |
| GLYCOPYRRONIUM / FORMOTEROL FUMARATE DIHYDRATE PRESSURIZED INHALATION SUSPENSION | 02473615 | Approved | |
| KAVIGALE | 02556332 | Approved | |
| SYMBICORT FORTE TURBUHALER | 02248218 | Approved | |
| SYNAGIS | 02438364 | Dormant | |
| SYNAGIS | 02438372 | Dormant | |
| ACCOLATE TAB 20 MG | 02236606 | Cancelled Post Market | |
| BETALOC DURULES TAB 200 MG | 00497827 | Cancelled Post Market | |
| BETALOC IV INJ 1 MG/ML | 00719846 | Cancelled Post Market | |
| BETALOC TAB 100 MG | 00402540 | Cancelled Post Market | |
| BETALOC TAB 50 MG | 00402605 | Cancelled Post Market | |
| BIQUIN DURULES 250 MG | 00249580 | Cancelled Post Market | |
| BRICANYL TAB 2.5 MG | 00335355 | Cancelled Post Market | |
| BRICANYL TAB 5 MG | 00335363 | Cancelled Post Market | |
| BYDUREON | 02448610 | Cancelled Post Market | |
| BYDUREON BCISE | 02483203 | Cancelled Pre Market | |
| BYETTA | 02361809 | Cancelled Post Market | |
| BYETTA | 02361817 | Cancelled Post Market | |
| CALCIUM CHLORIDE INJECTION 100MG/ML | 00705527 | Cancelled Post Market | |
| CALCIUM GLUCONATE 10% INJ 100MG/ML | 00707813 | Cancelled Post Market | |
| CARDURA-1,2,AND 4 | 02231762 | Cancelled Pre Market | |
| CASODEX | 02184478 | Cancelled Post Market | |
| DIMENHYDRINATE INJECTION 50MG/ML | 00705519 | Cancelled Post Market | |
| EVUSHELD | 02526271 | Cancelled Post Market | |
| FLUMIST QUADRIVALENT | 02426544 | Cancelled Post Market | |
| JECTOFER 50 MG/ML | 00001910 | Cancelled Post Market | |
| KOMBOGLYZE | 02389169 | Cancelled Post Market | |
| KOMBOGLYZE | 02389177 | Cancelled Post Market | |
| KOMBOGLYZE | 02389185 | Cancelled Post Market | |
| LOSEC 10 MG | 02230737 | Cancelled Post Market | |
| LOSEC CAPSULES 10MG | 02119579 | Cancelled Post Market | |
| LOSEC CAPSULES 40MG | 02016788 | Cancelled Post Market | |
| LYNPARZA | 02454408 | Cancelled Post Market | |
| NAROPIN INJ 7.5MG/ML | 02229416 | Cancelled Post Market | |
| NESACAINE CE 2% INJ 20MG/ML | 00613304 | Cancelled Post Market | |
| NESACAINE CE 3% INJ 30MG/ML | 00613312 | Cancelled Post Market | |
| NOLVADEX TAB 10MG | 02048477 | Cancelled Post Market | |
| NOLVADEX-D TAB 20MG | 02048485 | Cancelled Post Market | |
| ONDEXXYA | 02538539 | Cancelled Post Market | |
| PENGLOBE TAB 400 MG | 00627127 | Cancelled Post Market | |
| PENGLOBE TAB 800 MG | 00627135 | Cancelled Post Market | |
| POTASSIUM CHLORIDE INJECTION 2MEQ/ML | 00624756 | Cancelled Post Market | |
| QTERN | 02459175 | Cancelled Pre Market | |
| QTERN | 02459183 | Cancelled Pre Market | |
| RHINOCORT TURBUHALER 100 MCG/DOSE | 02035324 | Cancelled Post Market | |
| SALBUTAMOL NEBUAMP 0.05% | 02215616 | Cancelled Post Market | |
| SALBUTAMOL NEBUAMP 0.1% | 02215624 | Cancelled Post Market | |
| SALBUTAMOL NEBUAMP 0.2% | 02215632 | Cancelled Post Market | |
| SEROQUEL | 02240862 | Cancelled Post Market | |
| SODIUM BICARBONATE INJECTION 75MG/ML | 00701548 | Cancelled Post Market | |
| SODIUM BICARBONATE INJECTION 84MG/ML | 00701572 | Cancelled Post Market | |
| SODIUM CHLORIDE INJECTION 0.9% | 00624748 | Cancelled Post Market | |
| SODIUM CHLORIDE IRRIGATION SOLN 0.9% | 00709611 | Cancelled Post Market | |
| STERILE WATER FOR INJECTION | 00624721 | Cancelled Post Market | |
| TENORETIC 100/25MG TAB | 02049988 | Cancelled Post Market | |
| TENORETIC 50/25MG TAB | 02049961 | Cancelled Post Market | |
| THEO-DUR 100 MG | 00460982 | Cancelled Post Market | |
| THEO-DUR 200 MG | 00460990 | Cancelled Post Market | |
| THEO-DUR 300 MG | 00461008 | Cancelled Post Market | |
| THEO-DUR 450 MG | 00722065 | Cancelled Post Market | |
| TONOCARD TAB 400 MG | 00598941 | Cancelled Post Market | |
| VAXZEVRIA | 02510847 | Cancelled Post Market | |
| VAXZEVRIA | 02511444 | Authorization By Interim Order Revoked | |
| XYLOCAINE 0.5% | 00001724 | Cancelled Post Market | |
| XYLOCAINE 0.5% W EPINEPHRINE 1:100000 | 00001783 | Cancelled Post Market | |
| XYLOCAINE 0.5% W EPINEPHRINE 1:200000 | 00228915 | Cancelled Post Market | |
| XYLOCAINE 1.5% | 00001740 | Cancelled Post Market | |
| XYLOCAINE 1.5% W EPINEPHRINE 1:200000 | 00001813 | Cancelled Post Market | |
| XYLOCAINE 1.5% W EPINEPHRINE 1:200000 TEST DOSE | 00753149 | Cancelled Post Market | |
| XYLOCAINE 2% | 02229853 | Cancelled Post Market | |
| XYLOCAINE 2% EPIDURAL | 00284122 | Cancelled Post Market | |
| XYLOCAINE 2% W EPINEPHRINE 1:100000 | 00001821 | Cancelled Post Market | |
| XYLOCAINE 5% SPINAL | 00613673 | Cancelled Post Market | |
| XYLOCAINE CO2 INJ | 00276464 | Cancelled Post Market | |
| XYLOCAINE TOPICAL 4% | 00049816 | Cancelled Post Market | |
| XYLOCAINE TOPICAL 5% | 00284114 | Cancelled Post Market |
Medical device licences
Active licences first, newest first.
| Name | Licence | Status | First licensed |
|---|---|---|---|
| ASTRA SELF-ASPIRATING SYRINGE | 5191 | Discontinued at renewal · Class 2 | |
| ASTRA SELF-ASPIRATING SYRINGE | 5199 | Discontinued at renewal · Class 2 | |
| NOZZLES FOR XYLOCAINE ENDOTRACHEAL | 5204 | Cancelled · Class 2 | |
| NOZZLES FOR XYLOCAINE ENDOTRACHEAL - PLASTIC | 5206 | Cancelled · Class 2 |
Notices of Compliance
Newest first.
- IMFINZISeptember 24, 2026 · NOC 38337 · Supplement to a New Drug Submission (SNDS)
- ENHERTUSeptember 17, 2026 · NOC 38306 · Supplement to a New Drug Submission (SNDS)
- FLUMISTSeptember 11, 2026 · NOC 38264 · Supplement to a New Drug Submission (SNDS)
- ENHERTUAugust 27, 2026 · NOC 38183 · Supplement to a New Drug Submission (SNDS)
- IMFINZIAugust 21, 2026 · NOC 38153 · Supplement to a New Drug Submission (SNDS)
- KAVIGALEAugust 17, 2026 · NOC 38120 · Supplement to a New Drug Submission (SNDS)
- CRESTORAugust 12, 2026 · NOC 38092 · Supplement to a New Drug Submission (SNDS)
- FASENRA; FASENRA PENAugust 5, 2026 · NOC 38050 · Supplement to a New Drug Submission (SNDS)
- ETCAMAHAugust 4, 2026 · NOC 38047 · New Drug Submission (NDS)
- IMFINZIJuly 3, 2026 · NOC 37832 · Supplement to a New Drug Submission (SNDS)
- FLUMISTJune 19, 2026 · NOC 37730 · Supplement to a New Drug Submission (SNDS)
- ENHERTUMay 26, 2026 · NOC 37607 · Supplement to a New Drug Submission (SNDS)
- KAVIGALEApril 20, 2026 · NOC 37423 · Supplement to a New Drug Submission (SNDS)
- LYNPARZAApril 2, 2026 · NOC 37261 · Supplement to a New Drug Submission (SNDS)
- KOMBOGLYZEApril 1, 2026 · NOC 37250 · Supplement to a New Drug Submission (SNDS)
- XIGDUOApril 1, 2026 · NOC 37251 · Supplement to a New Drug Submission (SNDS)
- LOKELMAMarch 24, 2026 · NOC 37179 · Supplement to a New Drug Submission (SNDS)
- SAPHNELOMarch 5, 2026 · NOC 37042 · Supplement to a New Drug Submission (SNDS)
- NEXIUMFebruary 27, 2026 · NOC 37003 · Supplement to a New Drug Submission (SNDS)
- IMFINZIFebruary 20, 2026 · NOC 36949 · Supplement to a New Drug Submission (SNDS)
- TEZSPIREFebruary 9, 2026 · NOC 36867 · Supplement to a New Drug Submission (SNDS)
- CRESTORFebruary 5, 2026 · NOC 36853 · Supplement to a New Drug Submission (SNDS)
- BRILINTAFebruary 3, 2026 · NOC 36837 · Supplement to a New Drug Submission (SNDS)
- IMFINZIJanuary 22, 2026 · NOC 36769 · Supplement to a New Drug Submission (SNDS)
- LOKELMADecember 22, 2025 · NOC 36626 · Supplement to a New Drug Submission (SNDS)
- NOLVADEX-DNovember 5, 2025 · NOC 36330 · Supplement to a New Drug Submission (SNDS)
- TRUQAPOctober 29, 2025 · NOC 36283 · Supplement to a New Drug Submission (SNDS)
- ENHERTUOctober 27, 2025 · NOC 36272 · Supplement to a New Drug Submission (SNDS)
- TAGRISSOOctober 1, 2025 · NOC 36087 · Supplement to a New Drug Submission (SNDS)
- CALQUENCESeptember 11, 2025 · NOC 35986 · Supplement to a New Drug Submission (SNDS)
- FLUMISTAugust 28, 2025 · NOC 35919 · Supplement to a New Drug Submission (SNDS)
- WAINUAAugust 26, 2025 · NOC 35901 · Supplement to a New Drug Submission (SNDS)
- CALQUENCEJuly 31, 2025 · NOC 35772 · Supplement to a New Drug Submission (SNDS)
- FASENRA; FASENRA PENJuly 18, 2025 · NOC 35694 · Supplement to a New Drug Submission (SNDS)
- TEZSPIREJuly 18, 2025 · NOC 35697 · Supplement to a New Drug Submission (SNDS)
- IMFINZIJuly 17, 2025 · NOC 35692 · Supplement to a New Drug Submission (SNDS)
- ENHERTUJuly 3, 2025 · NOC 35646 · Supplement to a New Drug Submission (SNDS)
- ONGLYZAJune 24, 2025 · NOC 35565 · Supplement to a New Drug Submission (SNDS)
- CALQUENCEJune 24, 2025 · NOC 35572 · Supplement to a New Drug Submission (SNDS)
- LYNPARZAJune 23, 2025 · NOC 35552 · Supplement to a New Drug Submission (SNDS)
- IMJUDOJune 20, 2025 · NOC 35570 · Supplement to a New Drug Submission (SNDS)
- LYNPARZAMay 21, 2025 · NOC 35393 · Supplement to a New Drug Submission (SNDS)
- LYNPARZAApril 29, 2025 · NOC 35273 · Supplement to a New Drug Submission (SNDS)
- TAGRISSOApril 23, 2025 · NOC 35244 · Supplement to a New Drug Submission (SNDS)
- IMFINZIApril 10, 2025 · NOC 35152 · Supplement to a New Drug Submission (SNDS)
- IMFINZIApril 8, 2025 · NOC 35138 · Supplement to a New Drug Submission (SNDS)
- ENHERTUApril 4, 2025 · NOC 35200 · Supplement to a New Drug Submission (SNDS)
- KAVIGALEMarch 21, 2025 · NOC 35099 · New Drug Submission (NDS)
- FLUMISTJanuary 27, 2025 · NOC 34749 · Supplement to a New Drug Submission (SNDS)
- XIGDUOJanuary 22, 2025 · NOC 34714 · Supplement to a New Drug Submission (SNDS)
- FORXIGAJanuary 22, 2025 · NOC 34715 · Supplement to a New Drug Submission (SNDS)
- IMFINZIJanuary 17, 2025 · NOC 34705 · Supplement to a New Drug Submission (SNDS)
- ENHERTUJanuary 17, 2025 · NOC 34717 · Supplement to a New Drug Submission (SNDS)
- TRUQAPJanuary 3, 2025 · NOC 34631 · Supplement to a New Drug Submission (SNDS)
- ARIMIDEXDecember 23, 2024 · NOC 34604 · Supplement to a New Drug Submission (SNDS)
- LOKELMADecember 12, 2024 · NOC 34555 · Supplement to a New Drug Submission (SNDS)
- NOLVADEX - DNovember 12, 2024 · NOC 34368 · Supplement to a New Drug Submission (SNDS)
- CALQUENCEOctober 22, 2024 · NOC 34262 · Supplement to a New Drug Submission (SNDS)
- CRESTOROctober 11, 2024 · NOC 34192 · Supplement to a New Drug Submission (SNDS)
- IMFINZIOctober 8, 2024 · NOC 34169 · Supplement to a New Drug Submission (SNDS)
- TEZSPIREOctober 4, 2024 · NOC 34153 · Supplement to a New Drug Submission (SNDS)
- LYNPARZASeptember 27, 2024 · NOC 34112 · Supplement to a New Drug Submission (SNDS)
- BRILINTASeptember 20, 2024 · NOC 34061 · Supplement to a New Drug Submission (SNDS)
- FLUMIST QUADRIVALENTSeptember 16, 2024 · NOC 34067 · Supplement to a New Drug Submission (SNDS)
- FLUMIST QUADRIVALENTSeptember 13, 2024 · NOC 34017 · Supplement to a New Drug Submission (SNDS)
- TAGRISSOJuly 25, 2024 · NOC 33706 · Supplement to a New Drug Submission (SNDS)
- TAGRISSOJuly 19, 2024 · NOC 33674 · Supplement to a New Drug Submission (SNDS)
- TAGRISSOJuly 10, 2024 · NOC 33609 · Supplement to a New Drug Submission (SNDS)
- ENHERTUJuly 9, 2024 · NOC 33613 · Supplement to a New Drug Submission (SNDS)
- WAINUAJune 19, 2024 · NOC 33471 · New Drug Submission (NDS)
- BEYFORTUSJune 14, 2024 · NOC 33455 · Supplement to a New Drug Submission (SNDS)
- SAPHNELOJune 13, 2024 · NOC 33443 · Supplement to a New Drug Submission (SNDS)
- IMFINZIMay 29, 2024 · NOC 33332 · Supplement to a New Drug Submission (SNDS)
- LYNPARZAMay 22, 2024 · NOC 33278 · Supplement to a New Drug Submission (SNDS)
- IMJUDOMay 14, 2024 · NOC 33210 · Supplement to a New Drug Submission (SNDS)
- ENHERTUApril 10, 2024 · NOC 33035 · Supplement to a New Drug Submission (SNDS)
- EVUSHELDFebruary 22, 2024 · NOC 32812 · Supplement to a New Drug Submission (SNDS)
- CALQUENCEFebruary 13, 2024 · NOC 32693 · Supplement to a New Drug Submission (SNDS)
- TRUQAPJanuary 26, 2024 · NOC 32610 · New Drug Submission (NDS)
- IMJUDOJanuary 26, 2024 · NOC 32613 · Supplement to a New Drug Submission (SNDS)
- CRESTORJanuary 25, 2024 · NOC 32604 · Supplement to a New Drug Submission (SNDS)
- TEZSPIREJanuary 17, 2024 · NOC 32547 · Supplement to a New Drug Submission (SNDS)
- CRESTORJanuary 5, 2024 · NOC 32473 · Supplement to a New Drug Submission (SNDS)
- TAGRISSOJanuary 3, 2024 · NOC 32446 · Supplement to a New Drug Submission (SNDS)
- TAGRISSOJanuary 3, 2024 · NOC 32447 · Supplement to a New Drug Submission (SNDS)
- IMFINZIDecember 27, 2023 · NOC 32426 · Supplement to a New Drug Submission (SNDS)
- LYNPARZADecember 13, 2023 · NOC 32344 · Supplement to a New Drug Submission (SNDS)
- LOKELMADecember 8, 2023 · NOC 32322 · Supplement to a New Drug Submission (SNDS)
- KOMBOGLYZENovember 24, 2023 · NOC 32177 · Supplement to a New Drug Submission (SNDS)
- BRILINTANovember 14, 2023 · NOC 32087 · Supplement to a New Drug Submission (SNDS)
- XIGDUONovember 14, 2023 · NOC 32094 · Supplement to a New Drug Submission (SNDS)
- IMFINZIOctober 25, 2023 · NOC 31940 · Supplement to a New Drug Submission (SNDS)
- LYNPARZAOctober 24, 2023 · NOC 31938 · Supplement to a New Drug Submission (SNDS)
- FORXIGAOctober 11, 2023 · NOC 31828 · Supplement to a New Drug Submission (SNDS)
- BEYFORTUSSeptember 25, 2023 · NOC 31720 · Supplement to a New Drug Submission (SNDS)
- FLUMIST QUADRIVALENTSeptember 15, 2023 · NOC 31642 · Supplement to a New Drug Submission (SNDS)
- IMJUDOAugust 31, 2023 · NOC 31534 · New Drug Submission (NDS)
- IMFINZIJuly 20, 2023 · NOC 31264 · Supplement to a New Drug Submission (SNDS)
- LYNPARZAJuly 11, 2023 · NOC 31175 · Supplement to a New Drug Submission (SNDS)
- IMFINZIJuly 7, 2023 · NOC 31155 · Supplement to a New Drug Submission (SNDS)
The latest 100 of 460.
Recalls and safety alerts that mention its products
Health Canada’s recall notices do not carry licence numbers, so these are matched by name. A notice may cover another product or only some lots: read it to see what it covers.
- EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance to specific SARS-CoV-2 SubvariantsJanuary 17, 2023 · Biologic or vaccine · New safety information - Product safety - COVID
- EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral ResistanceOctober 26, 2022 · Biologic or vaccine · New safety information - Product safety - COVID
- Health Canada is updating the labels of the Janssen and Vaxzevria (AstraZeneca) COVID-19 vaccinesNovember 9, 2021 · Biologic or vaccine · Product safety - COVID
- Lynparza® (2018-02-23)February 23, 2018 · Drugs · Product safety · Type III
- FASLODEX (fulvestrant) - Risk of Unnecessary Therapy Modification due to Falsely Elevated Estradiol LevelsOctober 18, 2016 · Drugs · Product safety
- SGLT2 Inhibitors [INVOKANA (canagliflozin), FORXIGA (dapagliflozin), XIGDUO (dapagliflozin/metformin), JARDIANCE (empagliflozin)] - Risk of Diabetic KetoacidosisMay 16, 2016 · Drugs · Product safety
- Forxiga, Invokana: Health Canada begins safety review of diabetes drugs known as SGLT2 inhibitors and risk of ketoacidosisJune 22, 2015 · Drugs · Product safety
- Pulmicort Nebuamp - (0.125 mg/mL, 0.25 mg/mL, 0.5 mg/mL)February 18, 2013 · Drugs · Product safety · Type III
- Pulmicort Turbuhaler (budesonide) powder for oral inhalation - Potential device failure - For Health ProfessionalsJuly 26, 2012 · Drugs
- Pulmicort Turbuhaler (budesonide) powder for oral inhalation - Potential device failure - For the PublicJuly 26, 2012 · Drugs
- Important Safety Information on IRESSA (gefitinib) - For Health ProfessionalsOctober 11, 2007 · Drugs
- Archived - Iressa (gefitinib) - Advisories, Warnings, and Recalls for Health ProfessionalsDecember 12, 2006 · Drugs
- Archived - Iressa (gefitinib) 250 mg Tablets - Advisories, Warnings, and Recalls for Health ProfessionalsJune 5, 2006 · Drugs
- Important Safety Information on Oxeze (formoterol fumarate dihydrate) Turbuhaler – AstraZeneca Canada Inc. – For Health ProfessionalsSeptember 9, 2005 · Drugs · Product safety
- Iressa (gefitinib) 250 mg Tablets - Advisories, Warnings and Recalls for Health ProfessionalsAugust 26, 2005 · Drugs
- Association of CRESTOR® (rosuvastatin) with Muscle -Related Adverse Events – AstraZeneca Canada Inc. – For Health ProfessionalsMarch 11, 2005 · Drugs · Product safety
- Archived - Association of CRESTORMarch 8, 2005 · Drugs
- Archived - Accelerated deaths using Casodex® (bicalutamide) 150 mg in patients with localized prostate cancerAugust 26, 2003 · Drugs